このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Bioventus マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Rob Claypoole

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

Bioventus: Bullish On Path To Profitability

Jan 24

Bioventus: Reiterating Buy Thesis Following Q2 Earnings

Sep 08

Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M

Aug 11

CEO（最高経営責任者

Rob Claypoole (52 yo)

less than a year

在職期間

Mr. Robert E. Claypoole, also known as Rob, is President, Chief Executive Officer and Director of Bioventus Inc. from January 10, 2024. He was Executive Vice President and President, US for Mlnlycke Health...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Mark Singleton	Senior VP & CFO	2.3yrs	US$1.06m	0.054% $ 284.8k
Anthony D'Adamio	Senior VP	6.8yrs	US$924.52k	0.091% $ 478.6k
Robert Claypoole	President	less than a year	データなし	データなし
Mike Crowe	Senior Vice President of Operations	less than a year	データなし	データなし
David Crawford	Vice President of Investor Relations & Treasurer	no data	データなし	データなし
Katrina Church	Senior VP & Chief Compliance Officer	3.8yrs	データなし	0.027% $ 140.0k
Helen Leupold	Senior VP & Chief Human Resources Officer	1.2yrs	データなし	データなし
Larry Chen	Managing Director of China & Asia Pacific	3.3yrs	データなし	データなし

2.3yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: BVSの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Claypoole	President	less than a year	データなし	データなし
Guy Nohra	Independent Director	3.8yrs	US$153.23k	0.11% $ 572.9k
Johnathan Bartholdson	Independent Director	1.4yrs	US$211.70k	0.024% $ 124.5k
Martin Sutter	Independent Director	3.8yrs	US$150.73k	0.044% $ 232.9k
William Hawkins	Independent Chairman of the Board	3.8yrs	US$199.48k	0.31% $ 1.7m
Guido Neels	Independent Director	3.8yrs	US$148.23k	0.044% $ 232.9k
Susan Stalnecker	Independent Director	3.8yrs	US$165.73k	0.077% $ 403.2k
Mary Ladone	Independent Director	2.9yrs	US$158.23k	0.032% $ 166.6k
Philip Cowdy	Independent Director	3.8yrs	データなし	0.018% $ 96.1k
Patrick Beyer	Independent Director	2.7yrs	US$150.73k	0.029% $ 152.7k
Michelle McMurry-Heath	Independent Director	2.4yrs	US$156.98k	0.027% $ 143.1k

3.8yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: BVSの取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

Bioventus マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Bioventus Inc., Annual General Meeting, Jun 11, 2024

Senior VP & CFO notifies of intention to sell stock

Bioventus Inc Announces Executive Changes

Interim CEO & Director recently bought US$165k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bioventus Inc. to Report Q1, 2024 Results on May 07, 2024

Bioventus Inc., Annual General Meeting, Jun 11, 2024

Senior VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioventus Inc. Provides Earnings Guidance for the Year 2024

New major risk - Revenue and earnings growth

Bioventus Inc. to Report Q4, 2023 Results on Mar 12, 2024

Now 21% undervalued

Bioventus: Bullish On Path To Profitability

Bioventus Inc Announces Executive Changes

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Bioventus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Interim CEO & Director recently bought US$165k worth of stock

Price target increased by 29% to US$4.50

High number of new and inexperienced directors

Bioventus Inc. to Report Q2, 2023 Results on Aug 08, 2023

LifeNet Health, Inc. completed the acquisition of Wound Business of Bioventus Inc.

LifeNet Health, Inc. completed the acquisition of Wound Business of Bioventus Inc.

Bioventus Inc. announced delayed 10-Q filing

LifeNet Health, Inc. signed a definitive agreement to acquire Wound Business of Bioventus Inc.

Bioventus Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Holdings Corporation (NasdaqCM:SWKH).

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Holdings Corporation (NasdaqCM:SWKH).

Kirby Mcinerney LLP Announces the Filing of a Securities Class Action on Behalf Bioventus Inc. Investors

Bioventus Inc. Appoints John A. Bartholdson to the Board as A Class II Director

Bioventus Inc. Announces Impairment of Goodwill for the Three Months Ended October 1, 2022

Bioventus Inc. announced delayed 10-Q filing

Price target decreased to US$9.20

High number of new and inexperienced directors

Price target decreased to US$9.20

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Bioventus Inc. Revises Earnings Guidance for the Twelve Months Ending December 31, 2022

Bioventus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Bioventus: Reiterating Buy Thesis Following Q2 Earnings

Bioventus Inc. Announces Resignation of Stavros G. Vizirgianakis as Member of the Board of Directors

Price target decreased to US$16.40

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioventus Inc. Updates Earnings Guidance for the Full Year 2022

Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M

Bioventus Receives FDA 510(k) Clearance for SonaStar Elite

Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal

Bioventus Inc. to Report Q2, 2022 Results on Aug 11, 2022

Bioventus Inc. (NasdaqGS:BVS) completes the acquisition of Cartiheal Ltd for $450 million.

Bioventus Inc. Announces Executive Changes

Bioventus: Strong Value Gap, Insulated Via Leading Market Share

Price target decreased to US$19.40

First quarter 2022 earnings: EPS misses analyst expectations

Bioventus Inc. Reaffirms Earnings Guidance for the Full-Year 2022

Price target increased to US$21.20

High number of new and inexperienced directors

Bioventus Inc. Provides Preliminary Unaudited Earnings Guidance for the First Quarter of 2022

Bioventus Inc. to Report Q1, 2022 Results on May 10, 2022

Bioventus Inc. (NasdaqGS:BVS) acquired unknown remining majority stake in Cartiheal Ltd for approximately $450 million.

Bioventus: Thoughts After An Active First Year

Price target increased to US$21.20

Price target decreased to US$19.50

Full year 2021 earnings: EPS misses analyst expectations

Bioventus Inc. Receives 510(k) Clearance for StimRouter Pain Management Device

Bioventus Inc. Appoints Mark Singleton as Senior Vice President and Principal Accounting Officer, Effective March 21, 2022

Bioventus Inc. Appoints Mark Singleton as Senior Vice President and Principal Accounting Officer, Effective March 21, 2022

Bioventus Inc., Annual General Meeting, Jun 17, 2022

Bioventus Inc. to Report Q4, 2021 Results on Mar 10, 2022

Bioventus Inc. provides Earnings Guidance for the Fourth Quarter and Full-Year Ending December 31, 2021

Bioventus Inc. Receives US FDA Clearance for BoneScalpel Access

マネジメント基準チェック /24